VTRS · Earnings call · 2026Q2T · Full report

Clinical Trial Enrollment Strategy

Viatris Inc · 2026-08-06 · Importance 31 · Surprise 42

Management is allowing the sizable clinical study to continue enrolling rather than stopping early, citing the substantial time, energy, and money already invested. The company expects continued enrollment to generate more events and improve the data available for positioning the drug. Management said allowing the study to run until near data lock should reach the primary endpoint faster than stopping and waiting for events, with ClinicalTrials.gov enrollment ranges providing flexibility for the final patient count.

Key facts